Адъювантная андрогенная блокада после дистанционной лучевой терапии при раке предстательной железы — отдаленные результаты III фазы исследования RTOG 85-31

1. Zelen M. The randomization and stratification of patients to clinical trials. J Chron Dis — 1974;27:365—75.

2. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.

3. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat — 1988; 16:1141—54.

4. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Stat Assoc — 1958;53:457—81.

5. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep — 1966; 50:163—70.

6. Cox D.R. Regression models and life tables. J R Stat Soc Series B — 1972;34:187—229.

7. Pilepich M.V., Caplan R., Byhardt R.W. et al. Phase in trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group protocol 85—31. J Clin Oncol — 1997;15:1013—21.

8. Pilepich M.V., Winter K., John M.J. et al. Phase in RTOG trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys — 2001;50:1243—52.

9. Bolla M., Gonzalez D., Warde P. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med — 1997;337:295—300.

10. Bolla M., Collette L., Blank L. et al. Long term results with immediate androgen suppression and external irradiation in pa-tients with locally advanced prostate cancer (an EORTC study): A phase IE randomized trial. Lancet — 2002; 360:103—8.

11. Lawton C.A., Winter K., Murray K. et al. Updated results of the phase in RTOG trial 85-31: Evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys — 2001;49:937—46.

12. Pilepich M.F., Krall J.M., Sarraf M. et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized com-parative trial of the Radiation Therapy Oncology Group. Urology — 1995;45:616—23.

13. Laverdiere J., Gomez J.L., Cusan L. et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer . Int J Radiat Oncol Biol Phys — 1997;37:247—52.

14. Hanks G.E., Pajak T.F., Porter A. et al. Phase in trial of longterm adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol — 2003;21: 3972—8.

15. Stege R. Potential side-effects of endocrine treatment of long duration in prostate cancer. Prostate Suppl — 2000;10:38—42.

16. Berruti A., Dogliotti L., Terrone C. et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with cancer without apparent bone metastases given androgen deprivation therapy. J Urol — 2002; 167:2361—67.

17. Ross R.W., Small E.J. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol — 2002;167:1952—56.